Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCOAST-2 in resectable early-stage non-small cell lung cancer
2023-508852-21-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of durvalumab, rilvegostomig, volrustomig, oleclumab, monalizumab and 6 more in non-small cell lung cancer (NSCLC) (7 arms), sponsored by AstraZeneca. Primary endpoints: Pathologic complete response and Safety and tolerability. Planned start Jun 2022; status: authorised.
02
Drugs
durvalumabrilvegostomigvolrustomigoleclumabmonalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508852-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508852-21-00.